Made available in DSpace on 2015-05-08T14:47:24Z (GMT). No. of bitstreams: 1 arquivototal.pdf: 2003558 bytes, checksum: b444f3214b726140549bb7c59a5a2268 (MD5) Previous issue date: 2012-02-29 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES / Acquired immunodeficiency syndrome (AIDS), transmitted by Human Immunodeficiency Vírus (HIV) it attacks the immune system, which may cause adverse effects on the general state of health, and in particular, the hearing health. The objective of this study was to evaluate the hearing of children with HIV/AIDS and to assess the association of audiological findings in children with HIV/AIDS, relating them to the viral load, the opportunistic diseases and to antiretroviral treatment (TARV) instituted. We analyzed 23 children with HIV/AIDS that were followed at two specialized care services (SCS). Those responsible for the children responded to a questionnaire that included data on the clinical situation and the hearing health of children, which was subsequently complemented by information contained in medical records. Then, the external acoustic meatus was inspected and where necessary, the children were referred to the ent propitiate the realization of the audiological exams. The audiological evaluation was composed by examination of audiometry and immitanciometry (tympanometry and stapedial reflexes). For descriptive analysis of the data was used to the technique of inferential statistics, using Fisher's exact test, when the conditions for use of the test thur-square has not been verified. They were complied with the guidelines for research involving human beings contained in Resolution CNS N° 196/1996. There was an occurrence of hearing loss by ear in 84.8 % of the children analyzed, prevailing a percentage of 76.9 % of hearing loss discrete and 67.4 % for tympanometry curve type B. The otologic manifestations were observed in 65.2 % of the children, with the ear pain to the highest occurrence (66.7 %), there was no significant association with hearing loss (p=0.001). In relation to the association of hearing loss with the causal factor, there was no statistically significant association with the use of anti-retroviral therapy (p=0.031) and with the otitis (p=0.003), not showing for the variables viral load and the number of opportunistic diseases (p>0.05). The study showed the presence of hearing loss in children with HIV/AIDS, associated with the use of TARV and the otitis, but possibly not related solely to these, suggesting risks of damage to the linguistic development of children. The auditory follow in children with HIV/AIDS is important to diagnose and intervene as soon as possible on the possible causal factors of hearing loss, in order to preserve the hearing and to promote a development appropriate language, thus reducing the difficulties in the process of learning, education and social inclusion. / A Síndrome da Imunodeficiência Adquirida (AIDS) transmitida pelo Human Immunodeficiency Vírus (HIV) ataca o sistema imunológico, podendo causar repercussões sobre o estado geral de saúde e, de modo particular, à saúde auditiva. Objetivou-se avaliar a audição de crianças com HIV/AIDS e analisar a associação dos achados audiológicos em crianças com HIV/AIDS, relacionando-os à carga viral, às doenças oportunistas e ao tratamento antirretroviral (TARV) instituído. Foram analisadas 23 crianças com HIV/AIDS que estavam em acompanhamento em dois serviços de atendimento especializado (SAE). Os responsáveis pelas crianças responderam um questionário que continha dados sobre a situação clínica e a saúde auditiva das crianças, o qual foi posteriormente complementado por informações contidas em prontuário. Em seguida, foi realizada a inspeção do meato acústico externo e, quando necessário, as crianças foram encaminhadas ao otorrinolarigologista para propiciar a realização dos exames audiológicos. A avaliação audiológica foi composta pelo exame de audiometria tonal e imitanciometria (timpanometria e reflexos estapedianos). Para análise descritiva dos dados foi utilizada a técnica de estatística inferencial, através do teste Exato de Fisher, quando as condições para utilização do teste Qui-quadrado não foram verificadas. Foram respeitadas as orientações para pesquisa em seres humanos contidas na Resolução CNE N° 196/1996. Observou-se uma ocorrência de perdas auditivas por orelha em 84,8% das crianças analisadas, prevalecendo um percentual de 76,9% de perdas auditivas discretas e 67,4% para timpanometria de curva tipo B. As manifestações otológicas foram observadas em 65,2% das crianças, sendo a otalgia a de maior ocorrência (66,7%), havendo associação significativa desta com a perda auditiva (p=0,001). Em relação à correlação da perda auditiva ao fator causal, ocorreu associação estatisticamente significativa com o uso da terapia antirretroviral (p=0,031) e com a otite (p=0,003), não apresentando para as variáveis carga viral e o conjunto das doenças oportunistas (p>0,05). O estudo evidenciou a presença de perda auditiva nas crianças com HIV/AIDS, associada ao uso da TARV e da otite, mas possivelmente não relacionados exclusivamente a estes, sugerindo riscos de prejuízos para o desenvolvimento linguístico das crianças. O acompanhamento auditivo em crianças com HIV/AIDS é importante para diagnosticar e intervir o mais cedo possível sobre os possíveis fatores causais de perdas auditivas, a fim de preservar a audição e favorecer um desenvolvimento linguístico adequado, diminuindo as dificuldades no processo de aprendizagem, educação e inclusão social.

Introdução: Pacientes com infecção pelo HIV têm risco aumentado para o desenvolvimento de linfomas não-Hodgkin de células B comparado à população geral. Dentre os mecanismos que podem estar relacionados a esta patologia, encontra-se a reativação do vírus de Epstein-Barr secundária a imunossupressão. O papel do sistema imune para desenvolvimento de tumores é citado há longa data, e seu equilíbrio é mantido pelos linfócitos T regulatórios, cujo principal regulador e marcador é o fator de transcrição FOXP3. Neste estudo, avaliamos a presença de EBER e FOXP3 em amostras diagnósticas, além da carga viral para o vírus de Epstein-Barr em pacientes com linfomas relacionados à Aids a fim de avaliar e correlacionar os resultados como marcadores prognósticos nesta população. Métodos: Análise prospectiva da carga viral para Epstein-Barr no plasma e em células mononucleares do sangue periférico em 15 pacientes com linfomas relacionados à Aids acompanhados no Serviço de Hematologia do Instituto de Infectologia Emílio Ribas e do Hospital das Clínicas/Instituto do Câncer do Estado de São Paulo da Faculdade de Medicina da Universidade de São Paulo. As mensurações foram realizadas para cada paciente por reação da cadeia de polimerase em tempo real ao diagnóstico, término do tratamento e três meses após o término do tratamento. Dois grupos controles constituídos de 26 pacientes infectados pelo HIV em uso de anti-retroviral e sem diagnóstico de linfoma ou infecção oportunista e 30 indivíduos saudáveis também foram analisados para comparação da carga viral para o vírus de Epstein-Barr. Amostras coletadas por biópsia para o diagnóstico de linfoma foram submetidas a análise imuno-histoquímica para FOXP3 e para EBER por hibridização in situ. Resultados: 13 pacientes eram do sexo masculino e dois do sexo feminino, dos quais 14 foram tratados com quimioterapia e um com radioterapia de sistema nervoso central. Nove de 15 pacientes (60%) completaram o tratamento proposto e obtiveram remissão completa. A mediana da carga viral para o vírus de Epstein-Barr antes do tratamento foi 13 cópias/106 nas células mononucleares do sangue periférico (1-1472 cópias/106) e 70 cópias/mL (0-24900 cópias/mL) no plasma. Após o tratamento foi de 0,5/106 (0-109,5) e indetectável no plasma, com diminuição significativa da carga viral em células mononucleares do sangue periférico (p=0,022) e no plasma (p=0,003) ao término do tratamento em comparação ao diagnóstico. Nos pacientes em remissão completa, a carga viral para o vírus de Epstein-Barr diminuiu tanto no plasma como em células mononucleares do sangue periférico na maioria dos casos. A hibridização in situ para EBER resultou positiva em 7/15 (46,7%) casos, sendo significativamente superior no grupo de pacientes com linfomas relacionados a AIDS com mais de um sítio extralinfonodal comprometido (p=0,041) e com linfócitos T CD4 <100 células/L (p=0,026). A expressão de FOXP3 foi negativa em 15/15 (100%) dos pacientes com ARL. Conclusões: A expressão de EBER foi positiva em 7/15 (46,7%) dos pacientes com linfomas relacionados à Aids e superior de forma significativa nos pacientes com estádio mais avançado do linfoma e maior grau de imunossupressão. Observou-se diminuição estatisticamente significativa da mediana de carga viral para o vírus de Epstein-Barr em células mononucleares do sangue periférico (p=0,022) e plasma (p=0,003) após o tratamento do linfoma em comparação aos valores do diagnóstico em pacientes que atingiram remissão completa, o que poderia ser considerado um marcador prognóstico de resposta a terapia / Introduction: Patients with HIV infection have increased risk for development of non-Hodgkins lymphoma compared to general population. Among mechanisms that could be related to this disease is the reactivation of Epstein-Barr virus infection secondary to immunosuppression. The role of immune system in development of tumors was reported a long time ago, and balance of this system is maintained by regulatory T cells; FOXP3 transcription factor is the main regulator and marker of these cells. In this study we evaluated the presence of EBER and FOXP3 in diagnostic samples, and also viral load of Epstein-Barr virus in patients with Aids-related lymphoma to evaluate and correlate the results as prognostic markers in this population. Methods: Prospective analysis of viral load of Epstein-Barr virus in plasma and peripheral blood mononuclear cells from 15 patients with Aids-related lymphoma treated at Instituto de Infectologia Emílio Ribas and Hospital das Clínicas/Instituto do Câncer do Estado de São Paulo da Faculdade de Medicina da Universidade de São Paulo. Viral load measures were performed by real time polymerase chain reaction at diagnosis of lymphoma, completion of treatment and three months afterwards. Two control groups composed by 26 HIV-positive patients in use of HAART and without diagnosis of lymphoma or opportunistic infection and 30 healthy persons were also analyzed for viral load comparison. Biopsy samples performed to lymphoma diagnosis were submitted to immunohistochemistry for FOXP3 and in situ hybridization to EBER. Results: 13 patients were male and two females, 14 were treated with chemotherapy and one with radiotherapy of central nervous system. Nine of 15 patients (60%) completed treatment achieving complete remission. Median viral load of Epstein-Barr virus before treatment was 13 copies/106 in peripheral blood mononuclear cells (1-1472 copies/106) and 70 copies/mL (0-24900 copies/mL) in plasma. After treatment it was 0,5/106 (0-109,5) and not detectable in plasma, with significant decrease of viral load in peripheral blood mononuclear cells (p=0,022) and in plasma (p=0,003) after treatment compared to diagnosis. In patients with complete remission, viral load decreased in the majority of cases. In situ hybridization for EBER was positive in 7/15 (46,7%), and significant higher in the group of patients with Aids-related lymphoma with more than one extra nodal site (p=0,041) and CD4 T-cells <100 cells/L (p=0,026). FOXP3 expression was negative in 15/15 (100%) of patients with ARL. Conclusions: EBER expression was positive in 7/15 (46,7%) of patients with Aids-related lymphoma and significantly higher in patients with advanced stages of lymphoma and higher degree of immunosuppression. Significant decrease in median viral load of Epstein-Barr virus was observed in peripheral blood mononuclear cells (p=0,022) and plasma (p=0,003) after lymphoma treatment compared to diagnosis in patients that achieved complete remission, what could be considered a prognostic marker of response to therapy

Introdução: O emprego da terapia antirretroviral (TARV) proporcionou dramático impacto na mortalidade por aids e aumento na sobrevida. Entretanto, esse panorama depende da manutenção de altas taxas de adesão ao tratamento medicamentoso. A relevância da adesão tem sido reconhecida pelo Programa Nacional de DST e Aids desde o final dos anos 1990. Em que pese o destaque que o plano propositivo do Programa tem dado para a questão, ainda não dispõe de estudo atualizado sobre o número e tipo das atividades que estão em curso nos serviços. Este estudo teve por objetivo descrever as atividades de adesão em curso nos serviços de HIV/aids do Estado de São Paulo. Métodos: Foi enviado um questionário semi-estruturado para todos os 179 ambulatórios de HIV/aids do Estado, com perguntas sobre o tipo de serviço, pessoas sob TARV, formas e frequências de avaliação de adesão, atividades desenvolvidas (individuais, coletivas e para grupos específicos) e parcerias com organizações não governamentais. Para testar associação entre variáveis categóricas utilizou-se o teste Qui-quadrado de Pearson ou os testes exato de Fisher ou teste da razão de verossimilhanças, no nível de significância de p<0,05. A análise de agrupamento foi utilizada para investigar cada uma das associações de cada resposta com as variáveis: tamanho do município, tipo e tamanho das clínicas. Resultados: 136 dos ambulatório (76%) responderam à pesquisa. Quase todos (96,3%) relataram incentivar a adesão na prática clínica, predominantemente nas consultas de médicos (94,1%) e enfermeiros (67,6%). A maioria (78,7%) relatou avaliar a adesão através de registros da farmácia. Grupos (38,2%) e palestras (28,7%) foram as atividades de grupo mais conduzidas. A análise de agrupamento identificou três grupos de ambulatórios, dois deles muito distintos. Grupo 1 (27 ambulatórios) foi composto predominantemente por unidades de saúde básica, com menos de 100 pacientes, apresentaram a menor freqüência de avaliação da adesão e menos atividades individuais e em grupo. Grupo 2 (51 ambulatórios) foi constituído principalmente por ambulatórios especializados em HIV/aids, com mais de 500 pacientes, com maior freqüência de avaliação da adesão, maior participação de psicólogos, assistentes sociais e farmacêuticos e mais atividades individuais e em grupo. Grupo 3 (56 ambulatórios) foi composto em sua maioria por ambulatórios de especialidades e de médio porte, com a maioria das atividades semelhantes ao Grupo 2, exceto pela ausência de atividades para grupos específicos e menos envolvimento multidisciplinar. Conclusão: Dado o amplo reconhecimento da importância da adesão por parte das clínicas, ainda há poucas atividades específicas de adesão no Estado. As clínicas maiores e mais especializadas tendem a oferecer mais atividades individuais e em grupo, utilizando abordagens multidisciplinares. Maior atenção deve ser dada para a descentralização do atendimento às pessoas vivendo com HIV para assegurar cuidados de qualidade mais homogêneos em toda a rede ambulatorial. / Introduction: The use of antiretroviral therapy (HAART) has provided dramatic impact on AIDS mortality and improved survival. However, this scenario depends on maintaining high rates of adherence to HAART. The relevance of adherence has been recognized by the National STD/AIDS Program since the late 1990s. Despite the emphasis that the Program has given to the issue, there have been no study to date on the number and type of activities that are underway in the services. This study aimed to describe the HAART adherence support activities in Sao Paulo State HIV/AIDS clinics. Methods: We sent a semi structured questionnaire to all 179 HIV/AIDS clinics with questions about type of clinic, people on HAART, adherence assessment, activities (individual, group and for specific groups). To test association between categorical variables used the chi-square test or Fisher exact test or likelihood ratio test at a significance level of p <0.05. Cluster analysis was used to investigate each association of each answer with the variables: municipality size, type and size of the clinics. Results: 136 clinics (76%) answered the survey. Almost all (96.3%) reported encouraging adherence in clinical practice, particularly in the medical (94.1%) and nurse (67.6%) visits. Most (78,7%), reported assessing adherence by pharmaceutical records. Groups (38.2%) and lectures (28.7%) were the group activities most developed. Cluster analysis identified three groups of clinics; two of them were too different. Group 1 (27 clinics) was predominately composed by primary care clinics, with less than 100 patients, the lowest frequency of assessing adherence and fewer individual and group activities. Group 2 (51 clinics) predominately composed by HIV specialized clinics specializing, HIV/AIDS, with more than 500 patients, assessing adherence more frequently, with greater involvement of psychologists, social workers and pharmacists developing more individual and group activities. Group 3 (56 clinics) was predominately composed by medium size specialized clinics, with majority of activities similar to Group 2, except by the absence of activities to specific groups and less multidisciplinary involvement. Conclusion: Given the broad recognition of the adherence importance by the clinics, there are still few specific adherence activities. The larger and more specialized clinics tend to provide more individual and group activities, using multidisciplinary approaches. Greater attention should be given to the decentralization of care offered to people living with HIV to ensure more homogeneous quality care across the ambulatory network.

Depuis la description des premiers cas de SIDA pédiatriques en 1983, d’importants progrès ont été réalisés dans la compréhension des mécanismes de transmission, puis dans la prévention de celle-ci, et dans la connaissance de l’histoire naturelle de l’infection par le VIH chez l’enfant. Depuis 1996 les multithérapies ARV ont permis une diminution considérable de la transmission verticale et de la morbidité et mortalité des enfants infectés par le VIH.<p>Les buts de ce travail ont été :<p>• d’évaluer, dans le contexte de l’offre de soin mise en place dans un centre de référence,<p>l’impact de l’administration prophylactique des traitements ARV pendant la grossesse sur la transmission verticale du virus.<p>• de déterminer si l’instauration précoce d’un traitement ARV chez les enfants infectés à la naissance et encore asymptomatiques améliorait le devenir de l’enfant.<p>• de contribuer à l’évaluation de l’impact de l’exposition à la maladie maternelle et aux traitements ARV sur le devenir des enfants non infectés nés de mères infectées par le VIH.<p><p>Une étude rétrospective portant sur les enfants nés de mères infectées par le VIH et suivis à l’hôpital St-Pierre entre 1986 et 2002, nous a permis de comparer 3 cohortes de naissance correspondant à différents types de prise en charge. Nous avons pu montrer que le taux de transmission a diminué globalement de 10% durant la période précédant l’administration de prophylaxie ARV à 5% durant la troisième période où les multithérapies étaient recommandées en prophylaxie durant la grossesse. Nous avons montré<p>que chez les mères qui ne bénéficiaient pas de prophylaxie ARV le taux de transmission avait augmenté significativement entre 1986 et 2002; le plus souvent suite à une prise en charge trop tardive de la grossesse, à un dépistage tardif de la séropositivité maternelle, ou à une mauvaise compliance au traitement.<p>Chez le nouveau-né infecté par le VIH, la multiplication virale est beaucoup plus importante<p>et prolongée que lors de la primo-infection chez l’adulte. Parallèlement, l’évolution clinique de l’infection peut être rapide dans un quart des cas, et aboutir au SIDA ou au décès avant l’âge de 1 an, sans qu’il existe de bons facteurs prédictifs de cette évolution défavorable en début de vie. Jusqu’en 2007, les différentes recommandations internationales indiquaient de débuter un traitement chez les nourrissons infectés lors d’apparition de symptômes cliniques ou d’immunodépression. Cependant dès 1996, certains centres dans des pays industrialisés, dont l’équipe de pédiatrie du CHU St Pierre, ont décidé d’initier un traitement ARV chez tous les nourrissons infectés dès confirmation du diagnostic. En 2006, nous avons initié une étude rétrospective multicentrique incluant 13 cohortes européennes visant à étudier l’impact du traitement précoce sur l’évolution clinique et biologique de l’enfant. Les données de 210 enfants,nés entre 1996 et 2004 et infectés à la naissance ont été analysées, et ont permis de dé4<p>montrer que les enfants traités avant l’âge de 3 mois avaient un risque de développer un sida ou de décéder 5 fois inférieur aux enfants traités après cet âge. Des résultats similaires ont été observés dans une étude randomisée réalisée en Afrique du Sud et publiée simultanément. Depuis, les recommandations internationales ont été revues<p>et préconisent la mise sous traitement de tous les nourrissons infectés. L’analyse des données biologiques a permis de montrer que la réponse virologique immédiate était plus rapide avec un pic de charge virale moins élevé et que la chute des lymphocytes CD4 était moins prononcée lorsque le traitement était débuté précocement.<p>Avec la généralisation de la prophylaxie ARV pendant la grossesse, le nombre d’enfants exposés in utero au VIH mais indemnes de l’infection a considérablement augmenté.<p>Des études, menées principalement dans des pays en développement, ont révélé un risque accru de morbidité et de mortalité infectieuse ainsi que la survenue d’infections sévères inhabituelles chez ces enfants. Nous avons été frappés durant le suivi de ces enfants par la survenue d’un nombre élevé d’infections néonatales causées par le streptocoque du groupe B (GBS). La comparaison avec le taux d’infection observé dans une population contrôle (estimé sur base des naissances survenues pendant la même période dans le même hôpital) nous a permis de décrire une incidence 19 fois supérieure d’infection à GBS chez les enfants exposés au VIH et non infectés que chez les enfants contrôles. Il s’agit du premier travail publié évoquant une susceptibilité accrue aux infections des enfants exposés non infectés dans un pays industrialisé.<p>En conclusion, la prophylaxie ARV pendant la grossesse et en début de vie a permis de diminuer considérablement la transmission verticale de l’infection à VIH. Un dépistage manqué, une prise en charge tardive de la grossesse, ou la mauvaise adhérence au traitement sont encore responsables d’infection du nouveau-né. Lors de confirmation<p>d’infection du nourrisson par le VIH, il est très important de débuter un traitement le plus rapidement possible afin de contrôler rapidement la multiplication virale, de maintenir une bonne immunité et de prévenir le développement de la maladie. Enfin, en l’absence d’infection du nourrisson par le VIH, il est important de poursuivre le suivi pendant les premières années de vie puisqu’il semble que les enfants exposés au<p>VIH et non infectés soient plus susceptible aux infections sévères. Ceci a été démontré en ce qui concerne les infections néonatales à GBS. / Doctorat en Sciences médicales / info:eu-repo/semantics/nonPublished

Background: IPT is an effective, safe and feasible disease prevention scheme that should be administered for all PLHIV living in areas with high latent TB prevalence. Objective: To assess the impact of isoniazid in the incidence of tuberculosis among HIV infected individuals in Addis Ababa. Methods: A case control study design was undertaken among 489 HIV and TB infected patients in Addis Ababa from January 2008 to December 2010. Results: Tuberculosis incidence rate among those who developed TB after completing 6-9 month isoniazid preventative therapy was17.14 PYO compared to 10.28 PYO among those who were not. Isonizide reduced the chance of developing tuberculosis among HIV infected patients (OR= 0.072; 95% CI 0.044, 0.12). Age (AOR= 0.14; 95% CI 0.03, 0.97) and sex (AOR= 1.86; 95% CI 1.02, 2.23) of the patient, CD4 count at HIV diagnosis (AOR= 0.21; 95% CI 0.13, 0.31), clinical stage of HIV illness (AOR= 1.22; 95% CI 1.09, 1.84) and past tuberculosis history (AOR = 1.97; 95% CI 1.24, 3.67) were major factors associated with tuberculosis incidence. Conclusions: INH prophylaxis was associated with lower incidence of tuberculosis among PLHIV. / Health Studies / M. Public Health

Objetivo: Evaluar si existe asociación entre el abandono con la falla terapéutica en inmigrantes venezolanos con infección por el virus de inmunodeficiencia humana (VIH) que reinicien tratamiento antirretroviral de gran actividad (TARGA). Métodos: Llevamos a cabo una cohorte retrospectiva en el Hospital Nacional Arzobispo Loayza. Incluimos pacientes que reiniciaron tratamiento TARGA. La variable de resultado fue la falla terapéutica (FT), compuesta por falla inmunológica (FI), virológica (FV) y clínica (FC). La variable de exposición fue el abandono terapéutico, aquellos que no recibieron tratamiento por 30 días, de 30 días a seis meses y de seis meses a más. Las variables control fueron el sexo, la orientación sexual, el nivel de instrucción, la edad y comorbilidades. Utilizamos modelos lineales generalizados de Poisson con errores estándar robustos para calcular riesgo relativo a nivel crudo (RR) y ajustado por criterio estadístico (RRa1) y epidemiológico (RRa2). Resultados: Incluimos 294 pacientes, 47,7% de ellos abandonaron TARGA, 32,7% abandono menos de seis meses, 15% abandonó mas de seis meses y el 27,9% tenían FT. Comparado con aquellos que no abandonaron, un abandono menor a 6 meses [RRa1: 1,98 (IC95%: 1,27 a 3,09);] y de seis meses a más [RRa1: 3,17 (IC95%: 2,02 a 4,95);] incrementó el riesgo de FT. El abandono de hasta seis meses [RRa1: 2,32 (IC95%: 1,40 a 3,84)] y de seis meses a más [RRa1: 3,93 (IC95%: 2,39 a 6,45)]; aumentó el riesgo de FV. En el caso de la FC [RRa1: 1,96 (IC95%: 0,67 a 5,79)] y la FI [RRa1: 2,99 (IC95%: 0,87 a 10,30)] no encontramos evidencia estadística de asociación con el abandono terapéutico. Conclusiones: El abandono del TARGA incrementa el riesgo de FT y FV en pacientes inmigrantes venezolanos. Dentro de la valoración integral que los pacientes con VIH debe explorarse el abandono como una variable de alta a importancia. / Objective: To evaluate the association between antiretroviral treatment interruption with the treatment failure in adults with human immunodeficiency virus (HIV) infection that reinitiates (HAART). Methods: We carried out a retrospective cohort study at the Hospital Nacional Arzobispo Loayza. We included immigrant patients who reinitiate HAART. The outcome was treatment failure (TF) may be immunological (IF), virological (VF), and clinical (CF) failure. The exposure variable was antiretroviral treatment interruption. The control variables measured were sex, sexual orientation, educational level, age, and comorbidities. We performed linear Poisson models with robust standard errors to calculate relative risk at the crude level (RR) and adjusted by statistical and epidemiological criteria. Results: We included 294 in the analysis. 47.7% of them defaulted treatment, 32.7% abandoned less than six months, 15% abandoned more than six months and 27.9% did TF; 24.6% VF; 6.8% IF, and 6.4% CF. A treatment interruption less than 6 months [aRR: 1.98 (95% CI: 1.27 to 3.09);] and from six months to more [aRR: 3.17 (95% CI: 2.02 to 4.95)] increased the risk of TF. Likewise, treatment interruption of up to six months [aRR: 2.85 2.32 (95% CI: 1.40 to 3.84)] and from six months to more [aRR: 3.93 (95% CI: 2.39 to 6,45)]; increased the risk of VF concerning patients who did not abandon treatment. In the CF [aRR: 1,96 (IC95%: 0,67 a 5,79)] and IF [aRR: 2,99 (IC95%: 0,87 a 10,30)] case, we did not find statistical evidence of an association with the abandonment time. Conclusions: The HAART treatment interruption is associated with the development of therapeutic and virologic failure. Treatment interruption should be explored as a variable of high importance in the assessment of patients with HIV. / Tesis

MPH / Department of Public Health / Background: South Africa presently has a very high HIV burden. It has adopted the UNAIDS “90-90-90 targets” to curb its HIV burden. This target aims to attain sustained viral suppression in 90% of all persons receiving antiretroviral therapy. This is supported by several studies. Studies to observe if patients are achieving and sustaining viral suppression in Limpopo, South Africa, are few. Objective: To investigate the viral and immunologic responses of patients in Vhembe District to highly active antiretroviral therapy (HAART) between the 1st of January 2004 and 31st of July 2016. Methodology: This was a retrospective medical record review conducted in Vhembe District in rural Limpopo. It included the medical records of 1247 individuals from Thohoyandou Community Health Centre. Analysis was done using SPSS 24.0. To model the factors associated with virologic and immunologic responses, each independent variable was tested for association with the dependent variable (viral suppression and CD4 count increase of ≥ 50 cells/μL from baseline to 6 months). The independent variables included age, year of initiation, gender, marital status, baseline BMI, haemoglobin, clinical stage and estimated creatinine clearance. The Pearson Chi square (X2) was used for all categorical independent variables and the t-test, for all continuous independent variables, to test for association. The estimate used was a 95% confidence interval, and a p-value of < 0.05 was considered significant. Results: The study showed that 52.6% of individuals were in clinical stage I at baseline. Viral suppression (viral load < 50 copies/ml) at 6 months was 64% (n = 648), 72% (n =193) at 60 months and 94% (n = 16) at 132 months. Fifty-nine percent had consistent viral suppression for a period of at least 6 months. Consistent viral suppression (viral load < 50 copies/ml on at least one consecutive occasion without any intervening viral load > 50 copies/ml) for at least 54 months was only 14%, while 2.3% had a delay in switching from a failing regimen. The mean CD4 count at baseline was 227 cells/μL, and 538 cells/μL at 60 months. The mean CD4 cell count increase from baseline to 6 months was 190 cells/μL. The immuno-virologic discordance was 27%. Patients with higher baseline CD4 count and females were significantly (p = 0.001 and 0.031 respectively) more likely to achieve viral suppression at 6 months. Those below 45 years and females were v significantly (p = 0.011 and 0.043 respectively) more likely to achieve adequate CD4 count increase at 6 months. Conclusions: The proportion of individuals with viral suppression in the District increased from 6 months onwards, and is fairly adequate. However, sustainability of viral suppression, once attained, is low. Adequate immunologic response, however, seems high. Males and age group above 45 years appear to have poorer responses to HAART.

Purpose: The purpose of this study is to assess risk factors associated with TB co-infection in HIV/AIDS patients taking antiretroviral therapy (ART). Methodology: An observational, analytic, case-control and quantitative study was conducted on a randomly selected 367 HIV and AIDS patients of whom 92 of them were TB co-infected. Data collection was done by using self-structured questionnaire. Result: In this study, educational status, waste disposal system, monthly income, contact history with a patient of active tuberculosis or presence of a family member with active tuberculosis, drug adherence, knowledge on tuberculosis prevention and history of exposure to substance were factors independently associated with the occurrence of active tuberculosis among HIV and Aids patients taking ART. Conclusion: The findings highlight the need for on-going educational, informational and other interventions to address the risk factors of tuberculosis in HIV and Aids patients in order to decrease the rate of TB co-infection / Health Studies / M.A. Public Health

Few studies have assessed the optimum second line highly active anti-retroviral therapy (HAART) regimen in patients who had failed on the first-line HAART in resource-limited settings. This study aimed to compare the Protease inhibitor (PI)-based second line HAART regimens used in one clinic in Trinidad by comparing immunological, virological and clinical outcomes of patients on the different second line HAART regimens. The records of 35 treatment-experienced patients, over 21years of age and on PI-based regimens for at least six months, were analysed using SPSS version 20. The regimen containing TDF/FTC/AZT/LPV/r proved to produce superior outcomes compared to the other second line regimens. Due the small number of usable patients’ records, the findings cannot be generalised but indicate directions for future studies attempting to compare the treatment outcomes of different second line HAART regimens / Health Studies / M. A. (Public Health)

Poor decision making among clinicians to transferring human immune deficiency virus (HIV) patients into second-line antiretroviral therapy (ART) has led to an increase in morbidity and mortality to people living with HIV (PLHIV). No clear barriers are known for clinicians not switching their patients. This is a descriptive qualitative research aimed to discover obstacles that influence clinicians' decision making to transferring patients into second-line ART despite higher level resistance to first-line ART. The researcher applied a participatory action research framework to solve the identified barriers with clinicians. Using the research questions the researcher explored reasons, perceived barriers and enabling factors for clinicians delay in making decision to transferring HIV patients into second-line ART. In-depth semistructured interviews were conducted with 30 participants. Six thematic areas (a) clinicians' capacity to diagnose treatment failure, (b) laboratory investigations, (c) availability, access, and tolerability to second-line ART, (d) clinicians' perceptions on ARV medicines, (e) clients' readiness for ARV medicines, and (f) adherence and retention to ARV medicines were analysed using STATA. Readiness, adherence and retention to ART, knowledge, competence and experience on ART , lack of viral load testing, and shortage of second-line ART were the common major barriers for clinicians in determining transferring patients into second-line ART. The government of Tanzania should acknowledge and create participation, responsibility, and commitment strategies to reduce the observed barriers. Findings of this study generates knowledge and provide actionable plans to help clinicians easily identify HIV patients who are in need of second-line ART.